- The trend backdrop is active with a 2-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
ARCT
NASDAQ
Week ended 28 Aug 2026
Weekly Investor Report
Arcturus Therapeutics Holdings Inc · Healthcare · Biotechnology
Latest close
15.19 USD
12.9%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 92.7% above the Trend Line and sits at 51.9% of its 52-week range. The latest completed week returned 12.9%, after a 163.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 49/100 conviction, while the latest news-sentiment score is 52/100.
Setup score
59
out of 100
Latest Close
15.19 USD
28 Aug 2026
1W Return
12.9%
latest completed week
4W Return
163.7%
short-term follow-through
12W Return
108.1%
quarterly tape
Trend Breadth
26.9%
14 of 52 weeks active
Volume Ratio
2.6x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 36.60% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
12.9%
Latest completed week; four-week move 163.7%.
Indicator stack
22/91
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 36.60%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
49/100 conviction; expected move 18.6%.
News sentiment
52/100
31 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 92.7% above the Trend Line and sits at 51.9% of its 52-week range. The latest completed week returned 12.9%, after a 163.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1412-week average 0.09
12-week confirmation
Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
1 accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 163.7% over four weeks, 108.1% over 12 weeks, and -10.7% over one year. The current trend has remained active for 2 consecutive weeks.
Performance by holding period
Active trend streak2 weeks
Active weeks in one year14
Trend breadth26.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.10Latest activity-pressure read.
Pressure change260.4%Four-week change in activity pressure.
Leadership42.46Latest relative-leadership reading.
RS change189.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 16 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 82%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength5/100Blend of value, momentum, and quality. Underlying universe rank 96; rank 1 is best.
Value30/100Relative valuation strength. Underlying universe rank 71; rank 1 is best.
Quality7/100Profitability and accounting quality. Underlying universe rank 94; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth10/100Revenue and earnings growth. Underlying universe rank 91; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 9.8x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -110.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 83.2% Gross profit retained from each unit of revenue.
- Operating margin
- -364.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -304.2% Free cash flow generated from revenue.
- Return on invested capital
- -1997.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -79.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -5.2% Net share repurchases relative to market value.
- Shareholder yield
- -5.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
ARCT shows volatility options pressure with a 49/100 conviction score, put-call volume ratio of 0.64, expected move of 18.6%, and Sharemaestro trend signal active.
Conviction49/100
Expected move18.6%
Put/call volume0.64
Insider activity8 / 0
8 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment52/100
Weighted news tone is neutral across 31 relevant articles.
7 positive · 16 neutral · 8 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move18.6%Nearest-chain priced movement where available.
52-week drawdown-37.2%Distance below the 52-week high.
13-week volatility19.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Mar
3 Apr
1 May
29 May
26 Jun
24 Jul
28 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+63.4%Week of 21 Aug.
Worst week-19.0%Week of 15 May.
Latest week+12.9%Week of 28 Aug.
Shape of recent returns
Strong gains12
Modest gains2
Flat weeks0
Modest losses2
Sharp losses10
Recent vol19.8%13-week weekly-return volatility.
Base vol14.6%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew9.7% / -10.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average6.9%
Trend breadth65.0%
Trend65.0%active weekly trend signals
MD77.0%positive activity pressure
RS55.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average9.8%
Trend breadth76.0%
Trend76.0%active weekly trend signals
MD71.0%positive activity pressure
RS66.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape52/100
Trend, activity pressure, participation, and risk combine to a 52/100 tape read.
Indicator analysis32/100Latest 12-week confirmation: trend 2/12, activity pressure 7/12, relative leadership 2/12.
Activity pressure 0.14; No reversal markers Next-Week ExpectancyNegative 36.60%Next-week expectancy is negative with a 36.60% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors11/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 83; Small Cap Core rank 77 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Options61/100ARCT shows volatility options pressure with a 49/100 conviction score, put-call volume ratio of 0.64, expected move of 18.6%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 18.6% Sentiment52/100Weighted news tone is neutral across 31 relevant articles.
Arcturus, Moderna fall after BioNTech's cancer vaccine setback Insiders8 / 08 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 28 Aug 2026 | 15.19 USD | 12.9% | 7.88 USD | 17.79 USD | 1.10 | 42.46 | 9.6M | On |
| 21 Aug 2026 | 13.45 USD | 63.4% | 7.63 USD | 17.90 USD | 0.40 | 25.25 | 11.6M | On |
| 14 Aug 2026 | 8.23 USD | 11.1% | 7.43 USD | 18.01 USD | -0.22 | -26.49 | 3.6M | Off |
| 7 Aug 2026 | 7.41 USD | 28.6% | 7.40 USD | 18.15 USD | -0.59 | -34.92 | 3.1M | Off |
| 31 Jul 2026 | 5.76 USD | 4.2% | 7.38 USD | 18.28 USD | -0.69 | -47.51 | 1.7M | Off |
| 24 Jul 2026 | 5.53 USD | -8.6% | 7.39 USD | 18.45 USD | -0.32 | -50.17 | 2.5M | Off |
| 17 Jul 2026 | 6.05 USD | -13.2% | 7.41 USD | 18.63 USD | -0.08 | -47.50 | 2.6M | Off |
| 10 Jul 2026 | 6.97 USD | -4.3% | 7.43 USD | 18.81 USD | 0.10 | -43.05 | 2.8M | Off |
| 3 Jul 2026 | 7.28 USD | 5.8% | 7.45 USD | 18.99 USD | 0.11 | -40.48 | 3.1M | Off |
| 26 Jun 2026 | 6.88 USD | -8.6% | 7.44 USD | 19.13 USD | 0.14 | -44.18 | 2.6M | Off |
| 19 Jun 2026 | 7.53 USD | 8.0% | 7.44 USD | 19.27 USD | 0.21 | -42.59 | 1.3M | Off |
| 12 Jun 2026 | 6.97 USD | -4.5% | 7.40 USD | 19.38 USD | 0.26 | -46.21 | 1.5M | Off |
| 5 Jun 2026 | 7.30 USD | -7.8% | 7.41 USD | 19.50 USD | 0.41 | -43.21 | 2.4M | On |
| 29 May 2026 | 7.92 USD | 12.7% | 7.45 USD | 19.63 USD | 0.65 | -42.01 | 1.5M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.